Combined Therapy Excels for PsA, Obesity.

Groundbreaking trial results demonstrate that a combination therapy involving two key medications offers superior outcomes for patients battling psoriatic arthritis and obesity, showing significant advancements in disease management and overall well-being.

Trial Highlights Superiority

A significant Phase 3b clinical trial, named Together-PsA, has unveiled compelling data regarding the efficacy of a dual-drug approach for individuals dealing with active psoriatic arthritis (PsA) alongside obesity or being overweight, coupled with at least one weight-related health complication. The open-label study investigated the effects of administering Taltz and Zepbound concurrently versus using Taltz as a standalone treatment. Presented at the 2026 American Academy of Dermatology Annual Meeting and published simultaneously in Arthritis & Rheumatology, the findings at the 36-week mark confirmed that the combination therapy achieved its primary objective and all crucial secondary endpoints, demonstrating statistically significant advantages over Taltz monotherapy. Early indicators of reduced PsA disease activity were observed as soon as Week 4 in the group receiving both Taltz and Zepbound, even prior to any substantial weight reduction becoming apparent, suggesting a potent and rapid therapeutic effect.

Comprehensive Health Gains

Beyond merely managing PsA symptoms, the Taltz and Zepbound combination therapy yielded a remarkable increase in the proportion of patients reaching Minimal Disease Activity, a stringent benchmark for successful PsA treatment. This success was complemented by notable improvements across various aspects of patient health. Participants experienced reduced fatigue, enhanced physical function, and a better quality of life, particularly concerning mental health. Furthermore, the study indicated significant positive shifts in cardiometabolic health markers and reduced inflammation levels. The concurrent administration of Taltz and Zepbound also led to improvements in body mass index (BMI), body weight, systolic blood pressure, glucose levels, HbA1c, triglycerides, and total cholesterol. These benefits were considered nominally statistically significant when compared to the Taltz monotherapy group, underscoring the multifaceted advantages of the combined treatment regimen.